Quantcast

Latest Bcr-abl fusion protein Stories

2012-01-30 10:35:30

About one in five or six cases of adult leukemia in Western populations relates to so-called chronic myeloid leukemia, or CML.  Treatment of CML usually relies on inhibitors of the abnormal protein that causes the condition but some patients do not respond to treatment and efforts are underway to develop a supplementary approach, targeting the so-called JAK2 kinase.  Recent results from the groups of Veronika Sexl at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna)...

2011-08-09 06:00:00

SUNNYVALE, Calif., Aug. 9, 2011 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert® BCR-ABL Monitor test, now reporting results to the International Scale. The test is being released as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test, which runs on Cepheid's GeneXpert® System, detects the BCR-ABL mRNA transcript in the peripheral blood of patients with...

2010-12-13 21:01:47

Chronic myeloid leukemia (CML) was transformed from a fatal disease to a chronic condition by the development of a drug known as imatinib, which targets the protein that drives this disease (BCR-ABL). However, imatinib does not cure patients, they must take the drug lifelong, as disease recurs if they stop taking it. This is because imatinib does not kill all the CML cells; some, which are known as CML stem cells, persist. A key to therapeutically targeting CML stem cells is knowing whether...

2010-11-29 18:45:34

Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS). "MicroRNAs are elevated in many cancers, but in humans and mice, can upregulation of a microRNA actually cause the cancer? That's the question," says Whitehead Institute Founding Member...

2010-10-07 15:05:00

SUNNYVALE, Calif., Oct. 7 /PRNewswire/ -- Cepheid today announced an exclusive collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Together with other lab tests, monitoring levels of BCR-ABL transcripts in Ph+ CML patients will aid in patient management. The collaboration reflects the commitment shared by...

2010-07-26 08:00:00

WHITE PLAINS, N.Y., July 26 /PRNewswire/ -- Kareem Abdul-Jabbar, basketball legend and the NBA's all-time leading scorer, is asking his supporters to join him in taking a shot at beating cancer by joining his team - Team Kareem. In 2009, after Kareem's diagnosis with Philadelphia chromosome-positive chronic myeloid leukemia, (Ph+ CML), a slow progressing type of blood cancer(1), he initiated a CML education program with Novartis Oncology to show people that they are not alone in fighting...

2010-03-03 13:28:02

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing. The team, led by Dr Veronika Sexl from the University of Vienna, carried out their research on acute lymphoid leukaemia (ALL) and chronic myelogenous...

2009-12-05 10:00:00

Omacetaxine launches different attack on CML that is impervious to other therapies NEW ORLEANS "• Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology. The injectable drug omacetaxine achieved durable responses in some...

2009-12-01 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that eleven presentations on preclinical studies of the company's product candidates will be given at the upcoming American Society of Hematology (ASH) Meeting and Exposition in New Orleans, Louisiana from December 5-8, 2009. Rigel's R788, an oral Syk kinase inhibitor, will be discussed in two oral presentations by collaborators about its activity in distinct B-cell...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'